Background. Metformin has been reported to decrease insulin resistance and is associated with a lower risk of pregnancy-induced hypertension and preeclampsia. It is widely accepted that the placenta plays a crucial role in the development of preeclampsia. Our aim is to explore the effect of metformin on preeclampsia. Study Design. We examined control diet-fed (isocaloric diet) pregnant mice (CTRL group), pregnant mice fed a high-fat diet (HF group), and high-fat-diet-fed pregnant mice treated with metformin (HF-M group). The HF mice were fed a high-fat diet six weeks before pregnancy to establish a preeclampsia-like model; then, the group was randomly divided into a HF group and a HF-M group after pregnancy. Blood pressure, urine protein, pregnancy outcomes, protein expression, and histopathological changes in the placentas of all groups were examined and statistically analysed. Results. We observed that metformin significantly improved high blood pressure, proteinuria, and foetal and placental weights in the HF-M group compared with the HF group. Metformin significantly improved placental labyrinth and foetal vascular development in preeclampsia. In addition, metformin effectively increased matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) levels in the placenta. Conclusions. Our results suggest that metformin can improve preeclamptic symptoms and pregnancy outcomes.
As of February 2020, a new type of coronavirus infection (coronavirus disease 2019, COVID-19) has continued to occur in China, and confirmed cases of infection in pregnant women have been reported. Beijing Ditan Hospital Affiliated with Capital Medical University is the designated hospital for treatment of maternal-neonatal coronavirus pneumonia in Beijing. Optimized management, prevention, and control of coronavirus pneumonia during delivery in pregnant women is crucial to ensuring the safety of mothers and infants. According to the latest COVID-19 national management plan combined with the specialization of our hospital in infectious diseases, we propose a process for management of birth in pregnant women with COVID-19 to provide clinical guidance and instruction for midwifery institutions.